A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM
← catalyst calendarNCT06976606 · readout ≤ 346 d
Sponsored by Lexeo Therapeutics (industry) · LXEO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
40estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-23 | actual | When the study began enrolling |
| Primary completion | Jul 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Arrhythmogenic Cardiomyopathy
- PKP2-ACM
- PKP2-ARVC
Primary outcome
what the primary-completion date above is the date OFPremature ventricular contractions (PVC)
measured 12 months
Permalink · LXEO's whole pipeline · Catalyst calendar · Every registered study · What changed